Skip to content

Establishment and clinical application of neoadjuvant therapy effect evaluation system for rectal cancer based on artificial intelligence platform

Establishment and clinical application of neoadjuvant therapy effect evaluation system for rectal cancer based on artificial intelligence platform

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046275
Enrollment
Unknown
Registered
2021-05-12
Start date
2021-05-10
Completion date
Unknown
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rectal cancer

Interventions

case series:Nil

Sponsors

The Affiliated Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years, and the rectal cancer was diagnosed by colonoscopy. The general data of the patients (including age, sex, body mass index, tumor location, pathological classification, degree of differentiation, and clinical stage) were collected; 2. The patient received preoperative high-resolution pelvic MRI examination, and the clinical staging was T3-4N0 or any T, N1-2; 3. The patient and his family agree to receive NAT treatment; 4. Patients agreed to be included in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Distant metastases (lung, liver, pelvic cavity, etc.) were detected by CT preoperatively or no radical resection was assessed; 2. Patients who need NAT after multi-disciplinary Treatment (MDT) before surgery, but who refuse NAT, except those who require surgery; 3. Patients with serious organ dysfunction (such as liver and kidney dysfunction, heart failure, respiratory failure, etc.)or patients with systemic diseases (such as severe rheumatic immune disease or blood system disease, etc.); 4. Patients who have undergone complex abdominal surgery or have been assessed for severe abdominal adhesions; 5. Patients with severe abdominal infection, or other complicated cases affecting the evaluation of rectal cancer observation.

Design outcomes

Primary

MeasureTime frame
apparent diffusion coefficient;T staging;N staging;circumferential resection margin;extramural vascular invasion;

Countries

China

Contacts

Public ContactGao Yuan

The Affiliated Hospital of Qingdao University

gaoyuan@qdyy.cn+86 18661806303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026